Cointime

Human Immunology Biosciences

company

About

Human Immunology Biosciences is a biotechnology company focused on developing therapies for immune-mediated diseases.

  • 11 - 50

Highlights

Total Funding Amount
$120M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$120M
Industries
Biotechnology,Life Science,Medical,Product Research,Therapeutics
Founded date
Jan 1, 2021
Number Of Employee
11 - 50
Operating Status
Active

HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes.

Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the use of medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.

HI-Bio was established in 2021 in San Francisco, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$120M
Human Immunology Biosciences has raised a total of $120M in funding over 2 rounds. Their latest funding was raised on Nov 1, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 1, 2022 Series A $120M 1 ARCH Venture Partners — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Human Immunology Biosciences is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Yes Series A
Cointime
Chủ Đề
Công Ty